If 23andMe is acquired, merges with another company, or goes through bankruptcy, your personal and genetic data may be transferred to the new owner as a business asset.
This analysis describes what 23andMe's agreement states, permits, or reserves. It does not constitute a legal determination about enforceability. Regulatory applicability and practical outcomes may vary by jurisdiction, enforcement context, and individual circumstances. Read our methodology
This clause establishes the operational framework for data continuity during corporate transactions, ensuring genetic and health data classified as business assets remain accessible to successor entities. The provision addresses the status of personal information under standard business acquisition protocols rather than treating it as separately governed by user consent requirements.
The removal of this distinct high-severity provision on data transfer during corporate events reduces clarity on what happens to genetic data in M&A or bankruptcy scenarios.
View full change record →Given 23andMe's publicly reported financial difficulties and bankruptcy filing, this clause has immediate practical relevance — consumers' genetic data could be acquired by an unknown third party with potentially different data practices. Consumers concerned about this should consider deleting their account and requesting sample discard now.
How other platforms handle this
If we're involved in a reorganization, merger, acquisition, sale of some or all of our assets or other business transaction, depending on the circumstances, we may disclose any of the information described in Section 2 above...
Whenever we transfer personal data internationally, we use tools and transfer agreements to: make sure the data transfer complies with applicable law; and help to give your data the same level of protection as it has in the EU...
we may share data between our affiliates for the safety and security of our users and may take necessary actions if we believe you have violated these Terms, including banning you from our Services and/or our affiliates' services...
This provision is material to M&A due diligence and implicates CCPA requirements for successor entities to honor existing privacy commitments, as well as FTC guidance on data asset transfers in corporate transactions involving sensitive consumer …
Enforcement risk, jurisdiction flags, contract triggers, and due diligence action items.
Search "[your state] attorney general consumer complaint" to find your state's direct complaint form
ConductAtlas detected a major restructuring of Meta’s privacy policy that removed detailed consumer rights disclosures and relocated them to separate documents.
Your genetic data may be transferred to a new owner as a business asset. Here is what the Terms of Service actually say and what you can do right now.
Get the research letter
Companies change their terms quietly. We read every version and catch what actually changed. One email a week on the changes that matter and what they mean.
This clause establishes the operational framework for data continuity during corporate transactions, ensuring genetic and health data classified as business assets remain accessible to successor entities. The provision addresses the status of personal information under standard business acquisition protocols rather than treating it as separately governed by user consent requirements.
Given 23andMe's publicly reported financial difficulties and bankruptcy filing, this clause has immediate practical relevance — consumers' genetic data could be acquired by an unknown third party with potentially different data practices. Consumers concerned about this should consider deleting their account and requesting sample discard now.
ConductAtlas has identified this type of provision across 288 platforms. See the full comparison.
No. ConductAtlas is an independent monitoring service. We are not affiliated with, endorsed by, or sponsored by 23andMe.